NCT06784752 2026-04-16
NETTER-3
Novartis
Phase 3 Recruiting
Clinical Trials
21 trialsNCT07165132 2026-04-13
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
RayzeBio, Inc.
Phase 1 Recruiting
NCT05477576 2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3 Recruiting
NCT04727723 2026-03-20
REAL-LU
Novartis
Active not recruiting
NCT03833700 2026-02-27
A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)
Eisai Inc.
Phase 1 Active not recruiting
NCT04711135 2026-02-12
NETTER-P
Advanced Accelerator Applications
Phase 2 Active not recruiting
NCT03972488 2026-01-21
NETTER-2
Advanced Accelerator Applications
Phase 3 Active not recruiting
NCT03600233 2025-12-23
Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
TaiRx, Inc.
Phase 2 Active not recruiting
NCT06441331 2025-12-17
KinLET
ITM Solucin GmbH
Phase 1 Recruiting
NCT05636618 2025-11-24
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors
Perspective Therapeutics
Phase 1/2 Recruiting
NCT05364944 2025-11-17
OXTEND-01
Debiopharm International SA
Phase 1 Terminated
NCT05050942 2025-11-06
SORENTO
Camurus AB
Phase 3 Active not recruiting
NCT04919226 2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3 Active not recruiting
NCT02611024 2025-07-09
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
Phase 1/2 Completed
NCT04524442 2025-01-24
Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
Advanced Accelerator Applications
Phase 4 Completed
NCT06253897 2024-12-24
BackSOM
Ipsen
Completed
NCT04852679 2024-10-01
PALACE
Ipsen
Phase 3 Completed
NCT05997056 2024-07-16
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
Aadi Bioscience, Inc.
Phase 2 Recruiting
NCT03220217 2021-01-14
To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
Ipsen
Phase 2 Completed
NCT01994213 2019-01-22
A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Terminated
NCT03017690 2018-12-21
Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Ipsen
Completed